Zoetis price target lowered to $180 from $210 at Stifel

Stifel lowered the firm’s price target on Zoetis (ZTS) to $180 from $210 and keeps a Buy rating on the shares. 2024 was a “tough year” for Animal Health as Idexx Laboratories (IDXX), Elanco (ELAN) and Zoetis were down 26%, 19% and 17% year-over-year, respectively, the analyst tells investors. For Zoetis in 2025, positives include that key franchises remain resilient and the 2025 two-year stacked revenue growth is “around an all-time high,” and innovation likely accelerates, but the firm’s diligence identifies Librela safety concerns and it has lowered Librela estimates, the analyst added.